Palisade bio announces pricing of $12 million upsized underwritten public offering

Carlsbad, calif., aug. 12, 2022 (globe newswire) -- palisade bio (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced the pricing of an underwritten public offering for gross proceeds of approximately $12 million prior to deducting underwriting discounts and commissions and offering expenses.
PALI Ratings Summary
PALI Quant Ranking